Table 6 lists adverse reactions that have been identified during post-approval use of levofloxacin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a casual relationship to drug exposure.
|System/Organ Class||Adverse Reaction|
|Blood and Lymphatic System Disorders||pancytopenia aplastic anemia leukopenia hemolytic anemia [see Warnings and Precautions ( 5.6)] eosinophilia|
|Immune System Disorders||hypersensitivity reactions, sometimes fatal including: anaphylactic/anaphylactoid reactions anaphylactic shock angioneurotic edema serum sickness [ see Warnings and Precautions ( 5.6) ,( 5.7)]|
|Psychiatric Disorders||psychosis paranoia isolated reports of suicidal ideation, suicide attempt and completed suicide [see Warnings and Precautions ( 5.4)]|
|Nervous System Disorders||exacerbation of myasthenia gravis [see Warnings and Precautions ( 5.5)] anosmia ageusia parosmia dysgeusia peripheral neuropathy (may be irreversible) [see Warnings and Precautions ( 5.3)] isolated reports of encephalopathy abnormal electroencephalogram (EEG) dysphonia pseudotumor cerebri [see Warnings and Precautions ( 5.4)]|
|Eye Disorders||uveitis vision disturbance, including diplopia visual acuity reduced vision blurred scotoma|
|Ear and Labyrinth Disorders||hypoacusis tinnitus|
|Cardiac Disorders||isolated reports of torsade de pointes electrocardiogram QT prolonged [see Warnings and Precautions ( 5.11)] tachycardia|
|Respiratory, Thoracic and Mediastinal Disorders||isolated reports of allergic pneumonitis [see Warnings and Precautions ( 5.6)]|
|Hepatobiliary Disorders||hepatic failure (including fatal cases) hepatitis jaundice [see Warnings and Precautions ( 5.6), ( 5.8)]|
|Skin and Subcutaneous Tissue Disorders||bullous eruptions to include: Stevens-Johnson Syndrome toxic epidermal necrolysis Acute Generalized Exanthematous Pustulosis (AGEP) fixed drug eruptions erythema multiforme [see Warnings and Precautions ( 5.6)] photosensitivity/phototoxicity reaction [see Warnings and Precautions ( 5.14)] leukocytoclastic vasculitis|
|Musculoskeletal and Connective Tissue Disorders||tendon rupture [see Warnings and Precautions ( 5.2)] muscle injury, including rupture rhabdomyolysis|
|Renal and Urinary Disorders||interstitial nephritis [see Warnings and Precautions ( 5.6)]|
|General Disorders and Administration Site Conditions||multi-organ failure pyrexia|
|Investigations||prothrombin time prolonged international normalized ratio prolonged muscle enzymes increased|
While the chelation by divalent cations is less marked than with other fluoroquinolones, concurrent administration of levofloxacin tablets with antacids containing magnesium, or aluminum, as well as sucralfate, metal cations such as iron, and multivitamin preparations with zinc may interfere with the gastrointestinal absorption of levofloxacin, resulting in systemic levels considerably lower than desired. Tablets with antacids containing magnesium, aluminum, as well as sucralfate, metal cations such as iron, and multivitamin preparations with zinc or didanosine may substantially interfere with the gastrointestinal absorption of levofloxacin, resulting in systemic levels considerably lower than desired. These agents should be taken at least two hours before or two hours after oral levofloxacin tablet administration.
No significant effect of levofloxacin on the peak plasma concentrations, AUC, and other disposition parameters for R- and S- warfarin was detected in a clinical study involving healthy volunteers. Similarly, no apparent effect of warfarin on levofloxacin absorption and disposition was observed. However, there have been reports during the postmarketing experience in patients that levofloxacin enhances the effects of warfarin. Elevations of the prothrombin time in the setting of concurrent warfarin and levofloxacin use have been associated with episodes of bleeding. Prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests should be closely monitored if levofloxacin is administered concomitantly with warfarin. Patients should also be monitored for evidence of bleeding [see Adverse Reactions ( 6.2) and Patient Counseling Information ( 17)].
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.